[2010, amended 2019] 1.4.16 Offer all women who have had gestational hypertension a medical review with their GP or specialist 6 8 weeks after the birth. [2010, amended 1.5 Management of pre-eclampsia Assessing pre-eclampsia 1.5.1 Assessment of women with pre-eclampsia should be performed by a healthcare professional trained in the management of hypertensive disorders of pregnancy. [2010, amended 2019] 1.5.2 Carry out a full clinical assessment at each antenatal appointment for women with pre-eclampsia, and offer admission to hospital for surveillance and any interventions needed if there are concerns for the wellbeing of the woman or baby. Concerns could include any of the following: sustained systolic blood pressure of 160 mmHg or higher any maternal biochemical or haematological investigations that cause concern, for example, a new and persistent: rise in creatinine (90 micromol/litre or more, 1 mg/100 ml or more) or rise in alanine transaminase (over 70 IU/litre, or twice upper limit of normal range) or fall in platelet count (under 150,000/microlitre) signs of impending eclampsia signs of impending pulmonary oedema other signs of severe pre-eclampsia suspected fetal compromise any other clinical signs that cause concern. [2019] 1.5.3 Consider using either the fullPIERS or PREP-S validated risk prediction models to help guide decisions about the most appropriate place of care (such as the need for in utero transfer) and thresholds for intervention. 1.5.4 When using a risk prediction model, take into account that: fullPIERS is intended for use at any time during pregnancy PREP-S is intended for use only up to 34 weeks of pregnancy fullPIERS and PREP-S models do not predict outcomes for babies. [2019] To find out why the committee made the 2019 recommendations on assessment of women with pre-eclampsia and how they might affect practice see rationale and impact. 